Anuh Pharma Ltd

Anuh Pharma Ltd has a strong capital structure with a total equity of INR 3,260,248,000 and a low debt-to-equity ratio of 0.03, indicating a conservative approach to leverage. The company's liquidity position is characterized by a current ratio of 2.11, suggesting it has sufficient short-term assets to cover its short-term liabilities. However, the company has a negative net cash position after subtracting total debt, which could pose a liquidity risk. In terms of profitability, Anuh Pharma Ltd has a return on equity of 14.52% and a return on assets of 9.35%, which are key metrics for assessing the company's efficiency in generating profits from its equity and assets. These figures should be compared against the industry medians to determine if the company is outperforming or underperforming its peers. The company's revenue is primarily derived from the sale of active pharmaceutical ingredients and corticosteroids, with a focus on macrolides, anti-malarial, and anti-hypertension products. The geographic exposure and revenue concentration are not explicitly detailed in the provided data, but the company's operations are likely concentrated in the regions where it has manufacturing facilities and distribution networks. The growth trajectory of Anuh Pharma Ltd is not explicitly detailed in the provided data, but the company's revenue of INR 6,615,149,000 indicates a significant market presence. The outlook for the company's revenue and profitability will depend on factors such as market demand, regulatory changes, and competitive dynamics. The risk assessment for Anuh Pharma Ltd indicates a medium liquidity risk and a low dilution risk. The company's capital structure is relatively stable, but the negative net cash position after subtracting total debt could be a concern for investors. The company has not disclosed any recent events that would significantly impact its operations or financial position.